The Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium was formed in 2005 as a response to a need for a consortium that is focused on new drug studies in childhood leukemia and lymphoma. The TACL approach is to integrate translational laboratory research with early phase clinical trials to speed the progress of new therapy development for children with cancer. The most important aspect in successfully carrying out clinical trials is the hard work and dedication of the physicians, nurses, and staff of the consortium member institutions, and the willingness of patients and their parents to partner with the investigators in testing new drugs.
TACL consortium's mission is to develop innovative therapies for currently incurable leukemias and lymphomas of childhood.
The TACL Operations Center is located at Children's Hospital Los Angeles.